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IL-18 is not therapeutic for neovascular age-related macular degeneration
To the Editor: Up to 50 million people worldwide are afflicted with the devastating blinding disease age-related macular degeneration (AMD) [1] [2] [3] . The vast majority of patients have the currently untreatable 'dry' or atrophic form of AMD, which is characterized by NLRP3 inflammasome-driven degeneration of the retinal pigment epithelium (RPE) supportive cell layer 4, 5 . Blockade of the NLRP3 inflammasome is a next-generation therapeutic target in dry AMD; however, it was recently reported that inflammasome-mediated production of interleukin-18 (IL-18) potentially safeguards the retina against the other, often more visually devastating form of AMD-which patients with dry AMD are at greatly increased risk of developing-known as choroidal neovascularization (CNV) 6 . Therefore, before initiating inflammasome-targeting clinical trials, it is essential to directly and rigorously assess whether modulating IL-18 or the NLRP3 inflammasome affects RPE cell health and CNV.
Classically, neovascular AMD is characterized by invasion and leakage of immature blood vessels from the underlying choroid into the neural retina 2, 3 , which causes rapid and severe vision loss if not treated promptly. There is a great need to improve the available treatments for CNV: even with the current standard of care, blockade of vascular endothelial growth factor-A (VEGFA), substantial vision loss still occurs in one-third of patients with CNV after 7 years of therapy, at which time nearly all patients exhibit central retinal atrophy 7 , a finding that is consistent with the toxicity observed after VEGFA blockade in multiple cell types in rodent retinas 8, 9 . As such, there is a pressing need to develop improved, alternative antiangiogenic strategies to treat neovascular AMD.
The NLRP3 inflammasome, an innate immune complex, and the cytokine IL-18, which is processed into a mature form by inflammasome activation, have emerged as targets in atrophic AMD. NLRP3 activation or IL-18 upregulation has been identified in the RPE of human atrophic AMD donor eyes 5, 10, 11 , and inflammasome activation or IL-18 exposure induces cell death of the RPE 5, 11 . These studies suggest that inflammasome inhibition could be therapeutic for atrophic AMD 5, 12 . However, it was recently reported that blocking either NLRP3 or IL-18 activity inhibits neovascularization in a mouse model of CNV 6 . To resolve these discrepancies regarding the function of this innate immune pathway in CNV and determine the viability of modulating this pathway in various forms of AMD, we addressed the role of IL-18 and NLRP3 in CNV using the standard laser injury-induced model in mice 13 , which is widely used and has been predictive of therapeutic success in humans.
Data from experiments performed independently at five different laboratories (J.A., D.R.H., B.K.A., Y.O. and H.T.) showed that intravitreous administration of recombinant mouse IL-18 (MBL International) (Supplementary Methods) at doses ranging from 30 pg to 1 mg did not affect laser CNV in wild-type mice when compared to PBS injection (Fig. 1a-f and Supplementary Table 1) . Notably, experiments from two laboratories (J.A. and H.T.) found that doses of IL-18 comparable to those reported earlier 12 did not affect CNV. All five groups also tested higher levels of IL-18 than those tested previously. Laser injury parameters were varied across each of the five laboratories to explore whether such technical differences could elicit differential sensitivity to IL-18 at different doses (Supplementary Methods), yet none of the research groups observed any modulatory effect of IL-18 on CNV. Laser CNV volumes are typically measured 1 week after laser injury ( Fig. 1) , but we also found that IL-18 (100 ng) did not modulate CNV volume 2 weeks after laser injury (Supplementary Fig. 1a) .
IL-18 comprises 98.81% of the recombinant IL-18 preparation (determined by PAGE and provided by the manufacturer, MBL International, lot 043). To rule out the possibility that the small fraction of other material in the recombinant IL-18 preparation might be proangiogenic, thereby counteracting the purported antiangiogenic activity of IL-18, we first tested whether the concentration of sucrose (1%) in the recombinant IL-18 diluent affected CNV. We found that sucrose (1%) did not change CNV compared to PBS ( Supplementary  Fig. 1b) . Next, we reasoned that testing the effects of the recombinant IL-18 preparation in Il18r1 -/-mice would unmask the potential proangiogenic activity of its non-IL-18 components, as IL-18 would be biologically silent in these mice, which lack its cognate receptor. The recombinant IL-18 preparation did not increase CNV volume in Il18r1 -/-mice ( Supplementary Fig. 1c) , indicating that the diluent and excipients in the IL-18 preparation from MBL International are not proangiogenic. We also tested another source of recombinant mouse IL-18, US Biological, and found that this preparation also did not modulate CNV in doses ranging from 1 ng to 1 mg (Supplementary Fig. 1d ). Moreover, in vivo transfection of RPE cells by subretinal injection of expression plasmids encoding the inactive precursor form of mouse IL-18 (pro-IL-18) or active (mature) mouse IL-18 did not reduce CNV volume in wild-type mice ( Supplementary  Fig. 2a) ; we confirmed protein expression from the plasmids using western blotting and immunofluorescence ( Supplementary Fig. 2b,c ). These data demonstrate that IL-18 is not antiangiogenic in the mouse model of laser-induced CNV.
Recombinant IL-18, at a dose within the range that did not affect CNV lesion size (Fig. 1) , induced RPE degeneration in wild-type mice (Supplementary Fig. 3a) , as did an expression plasmid for the mature, active form of IL-18 ( Supplementary Fig. 3b ). Overexpression of pro-IL-18, the inactive IL-18 precursor, did not induce RPE degeneration in wild-type mice, nor did overexpression of mature IL-18 in Il18r1 -/-mice ( Supplementary Fig. 3b ). The health of RPE cells, which subserve the neural retina, is essential for vision, and RPE loss is a hallmark of atrophic AMD. In atrophic AMD, RPE degeneration induces secondary loss of photoreceptors. Consistent with the observed RPE npg
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Next, we dialyzed the ab71495 antibody to remove substances with molecular weights less than 10,000 Da (including glycerol, 92 Da, and thimerosal, 405 Da), achieving a depletion of 99.95% of the glycerol from the antibody preparation ( Supplementary Fig. 4a ). We found that in contrast to nondialyzed ab71495, the dialyzed (glyceroldepleted) antibody did not increase CNV volume in wild-type mice ( Supplementary Fig. 4a ). After dialysis, the only remaining known constituent in the diluent would be 1% BSA. Ruling out any confounding effects of BSA, we found that 1% BSA did not affect CNV in wild-type mice (Supplementary Fig. 4c ).
Further implicating glycerol as the proangiogenic component of the IL-18-specific antibody ab71495, we found that a different IL-18-neutralizing antibody (D048-3, MBL International), used at a dose (30 ng) containing 67 times less glycerol than ab71495 (or Abcam diluent) per injection, did not increase CNV in wild-type mice. Three groups (J.A., H.T. and D.R.H.) demonstrated that D048-3, which prevents RPE degeneration in a mouse model of inflammasome-induced dry AMD when used at this dose 5 , did not change CNV volume when compared to an isotype IgG control or when dialyzed ( Fig. 2f and Supplementary Fig. 5a,b) . J.A.'s group also injected 1 mg of dialyzed MBL D048-3 and found that it had no effect on CNV volume (Supplementary Fig. 4b ). These data indicate that the proangiogenic effect of the antibody to pro-IL-18 reported previously 6 is due to glycerol, not to IL-18 neutralization, and that endogenous IL-18 does not drive CNV.
We also found that mice genetically deficient for either Il18 or its cognate receptor Il18r1 exhibited reduced CNV size compared to wild-type mice (Supplementary Fig. 5c,d) , contrary to the proposition that IL-18 is antiangiogenic in CNV 6 . Indeed, these data imply that developmental loss of IL-18 function creates a microenvironment that responds to injury with reduced angiogenesis. degeneration, wild-type mice treated with recombinant IL-18 showed decreased a-and b-wave amplitudes on electroretinograms, as compared to control PBS injection (Supplementary Fig. 3c ). In addition, we detected expression of the IL-18 receptor (IL-18R1) in the RPE of normal human eyes by immunostaining (Supplementary Fig. 3d ). Thus, it seems reasonable to speculate that increasing IL-18 levels in the retina could lead to RPE degeneration and, consequently, severe vision loss in humans. Moreover, the plausibility of this idea is congruent with our findings of increased IL-18 expression in human eyes with atrophic AMD 5 . Altogether, these data do not support the notion that IL-18 is antiangiogenic for CNV and, notably, demonstrate that intraocular IL-18 administration (40-100 ng in mice) is toxic to the retina. Furthermore, Doyle et al. 12 showed that an even lower dose of IL-18 (3 ng) resulted in molecular and visual pathology at just 24 h after intravitreous administration. Therefore, IL-18 therapy could pose a threat to vision and carries the risk of harming the sight of patients.
Although we found that delivery of exogenous IL-18 did not reduce CNV volume, we also tested whether blockade of endogenous IL-18 would affect CNV. It was reported previously that intravitreous administration of an IL-18-specific antibody increased CNV lesion size, purportedly through neutralization of endogenous IL-18 (ref. 6). However, that experiment compared eyes treated with this antibody to eyes treated with a sham injection, i.e., lack of any injection. We carried out an identical experiment using biologically and chemically robust controls: intravitreous administration of the isotype control IgG prepared in either PBS or the diluent used for the IL-18-specific antibody. The IL-18-specific antibody used in the previous study 6 was formulated in a high concentration (50%) of glycerol, a known proangiogenic molecule 14 . We therefore investigated whether this antibody increased CNV not because of IL-18 targeting but rather as a result of the glycerol content of the diluent.
First, two groups (J.A. and D.R.H.) reproduced the finding that the IL-18-specific antibody (Abcam, ab71495) used previously 6 increased CNV volume in wild-type mice when compared to an isotype IgG diluted in PBS or sham, i.e., no injection (Fig. 2a,c) . Next we tested the hypothesis that the glycerol in the diluent for the ab71495 preparation was responsible for the observed increase in angiogenesis. Intravitreous administration of glycerol induced a dose-dependent increase in CNV volume in wild-type mice (Fig. 2b) . The glycerol-containing Abcam diluent alone increased CNV volume in wild-type mice compared to sham or PBS injection to a similar extent as ab71495 or isotype IgG constituted in Abcam diluent (Fig. 2c) . In contrast, we observed no increase in CNV volume for isotype IgG constituted in glycerol-free buffer. In addition, both the IL-18-specific antibody ab71495 and isotype IgG constituted in Abcam diluent increased CNV volume in Il18 -/-mice similarly (Fig. 2d) , confirming that their proangiogenic effects occurred independently of IL-18 blockade. Moreover, consistent with the concept that glycerol has proangiogenic properties, neither ab71495 in diluent nor diluent alone increased CNV in mice deficient for aquaporin-1 (AQP1; Fig. 2e) , a membrane channel protein that is permeable to glycerol 15 and promotes angiogenesis 16 . 
In a recent study, Doyle et al. 12 reported that intravitreous administration of recombinant IL-18 (a proprietary GlaxoSmithKline formulation) inhibited laser CNV in wild-type mice. However, their data consisted only of a single dose (3 ml of 50 ng ml -1 , or 150 pg) of a single IL-18 preparation. Apart from the lack of any dose-response study (in contrast to our 5-log dose range, which included 150 pg and should overcome any differences in bioactivity between preparations), their report also lacked any supporting loss-of-function studies, such as an IL-18R1-deficient system, to support the concept that angiosuppression in their model results from a specific biological effect of IL-18. Moreover, the complete composition of their recombinant IL-18 preparation was not disclosed, nor were the individual components tested in CNV; as we have demonstrated, the chemical constituents of these biological preparations can profoundly modulate angiogenesis. Another potential source of discrepancy could be the degree of experimental variation: the CNV volumes in vehicletreated eyes in Doyle et al. 12 varied threefold between experiments, thereby hindering unambiguous differentiation of drug effects from experimental variability.
Doyle et al. 12 also assessed the effect of systemic administration of IL-18 on laser-induced CNV by administering it subcutaneously in different dosing regimens. Curiously, they reported that this route of IL-18 delivery was equally effective if administered either every day beginning 1 d before laser injury or in a single dose 14 d before laser injury. The half-life of IL-18 in the serum of mice is 16 h 17 ; therefore, at the time of laser injury, the administered IL-18 in mice receiving the second dosing regimen would have undergone 21 half-lives. At the reported effective single dose (1 mg kg -1 ), the amount of recombinant IL-18 remaining in the entire mouse at 14 d after subcutaneous administration, at the time of laser injury, would be approximately 12 pg (25 mg/2 21 ), assuming a total body mass of 25 g. Assuming uniform distribution throughout the body, the amount of recombinant IL-18 in the mouse choroid (~1 mg mass)-the site of CNVwould be approximately 0.5 fg. Surprisingly, this amount of IL-18 was reported to be as effective in inhibiting CNV volume as a dose containing 2.1 million times as much IL-18 administered daily (also subcutaneously). More confusingly, the same dose administered 1 d before laser injury (but not thereafter) was reported to be completely ineffective in inhibiting CNV. Collectively, the data presented by Doyle et al. 12 are both perplexing and difficult to reconcile with a biological model of IL-18 signaling. Moreover, systemic IL-18 administered to mice at a dose 4-40 times lower than that used by Doyle et al. 12 has been reported to induce cardiac dysfunction [18] [19] [20] ; the effects of such cardiac toxicity on CNV are unknown.
Although inflammasome-targeting drugs have not yet entered clinical trials for AMD, this next-generation treatment strategy is slated to be investigated in the near future. However, inflammasome targeting in preclinical investigations has not been limited to IL-18 blockade but has also extended to more upstream, common processing events. If a broad approach to inhibiting inflammasome activation were pursued-for example, by targeting the inflammasome machinery that processes IL-18 (and other cytokines) instead of blocking IL-18 directly-it would be important to determine whether such general inflammasome inhibition has any effect on CNV. Therefore, we sought to test more generally whether NLRP3 inflammasome activation influences CNV using genetic ablation and pharmacological inhibition targeting the core inflammasome genes Nlrp3, Pycard and Casp1.
CNV volume was unchanged in mice deficient in Casp1, Nlrp3 or Pycard compared to wild-type mice (Supplementary Fig. 6a) . Similarly, intravitreous administration of cell-permeant cholesterolconjugated, nonimmunogenic 17+2-nt siRNAs 21 targeting Nlrp3 or Pycard in wild-type mice did not change CNV size compared with control siRNA administration (Supplementary Figs. 6b and 7) . In addition, intravitreous administration of a peptide inhibitor of Fig. 6c ). Collectively, these data indicate that NLRP3 inflammasome targeting does not affect CNV. The development of new antiangiogenic strategies to treat neovascular AMD is an important pursuit in providing much-needed improvements to current standard-of-care therapy. IL-18 has been reported to promote 22, 23 and suppress 24, 25 angiogenesis in various systems. Here we found that modulating IL-18 levels has no impact on CNV progression. Consistent with the concept that inflammasome inhibition is a safe and viable therapeutic option for AMD, the other major cytokine produced by NLRP3 inflammasome activation, IL-1b, was found to promote CNV, and its blockade reduced CNV progression without negatively affecting photoreceptor health 26 . It is not clear why in two of our experiments (Supplementary Figs. 5 and 6a) we did not reproduce the results from previous work 6 , although it is possible that differences in the experimental animals (for example, the genetic background of the mice or the age of the mice, neither of which was indicated in detail in ref. 6 ) or in techniques (for example, laser CNV parameters 27 ) account for these discrepancies. Differences in gene-environment interactions or in the microbiome of the mice might also contribute to the observed differences 28, 29 .
Our work cautions against intraocular administration of IL-18 for the treatment of CNV, although it is also important to recognize that the laser burn-induced neovascularization model in mice used here and by Doyle et al. 12 might differ markedly from CNV in human AMD. In this respect, the translation of findings in mice to humans can be hampered by the nonsynonymity of immune responses in inflammatory diseases between these species 30 .
Our work also highlights the need for guarded interpretation of experiments that are not rigorously controlled. Consistent with precedent literature describing the proangiogenic nature of glycerol [14] [15] [16] , we showed that the IL-18-specific antibody reported previously to induce angiogenesis 6 did so only because it is formulated in glycerol and not because it neutralized IL-18. Our findings support the idea that inhibition of NLRP3 or IL-18, which has been proposed for treatment of dry AMD, Alzheimer's disease, atherosclerosis and diabetes, might not exacerbate coincident CNV. 
